Norgine acquires Azanta from European Equity Partners

Terms of the deal were not disclosed. According to publicly available information, Norgine, through its debt-financing entity Norgine Ventures, had been a minority shareholder in Azanta since 2014. Meanwhile, EEP acquired a majority stake in the business in 2015. Other minority shareholders included the company's management.

As a result of the transaction, Norgine wholly acquires Azanta's portfolio of products and strengthens its position as a European specialist pharmaceutical company.

The Dutch company had sales of €419m in 2019 and has a direct presence in 12 European countries, as well as in Australia and New Zealand.

Company
Founded in 1994 and headquartered near Copenhagen, Azanta is a speciality biopharmaceutical company that focuses on oncology, women's health and addiction medicine. It has sales subsidiaries in other Nordic countries and in France. The company recorded sales of DKK 43.3m in 2018.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Nordics
• Trade sale
• Denmark
• Pharmaceuticals